CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Intellia Therapeutics
NTLA
$1.22B
| $33.3K | 0.01% |
954
+88
| +10% | +$3.07K |
|
152
Harmony Biosciences
HRMY
$2.12B
| $33.2K | 0.01% |
603
+49
| +9% | +$2.7K |
|
153
Ultragenyx Pharmaceutical
RARE
$2.89B
| $33K | 0.01% |
712
+56
| +9% | +$2.59K |
|
154
Legend Biotech
LEGN
$6.41B
| $32.8K | 0.01% |
658
+159
| +32% | +$7.94K |
|
155
Prothena Corp
PRTA
$441M
| $29.6K | 0.01% |
491
+52
| +12% | +$3.13K |
|
156
AbCellera Biologics
ABCL
$1.25B
| $29.4K | 0.01% |
2,906
+236
| +9% | +$2.39K |
|
157
PTC Therapeutics
PTCT
$3.92B
| $27.9K | 0.01% |
731
+61
| +9% | +$2.33K |
|
158
Insmed
INSM
$28.8B
| $27.5K | 0.01% |
1,376
+252
| +22% | +$5.04K |
|
|
BPMC
159
DELISTED
Blueprint Medicines
BPMC
| $26.6K | 0.01% |
608
+49
| +9% | +$2.15K |
|
|
MRTX
160
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26.5K | 0.01% |
585
+64
| +12% | +$2.9K |
|
|
ISEE
161
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $26.3K | 0.01% |
1,227
+121
| +11% | +$2.59K |
|
162
Acadia Pharmaceuticals
ACAD
$4.38B
| $26.2K | 0.01% |
1,645
+130
| +9% | +$2.07K |
|
163
Akero Therapeutics
AKRO
$3.74B
| $26K | 0.01% |
475
+123
| +35% | +$6.74K |
|
164
Xenon Pharmaceuticals
XENE
$2.98B
| $25K | 0.01% |
635
+52
| +9% | +$2.05K |
|
165
Amylyx Pharmaceuticals
AMLX
$836M
| $24.9K | 0.01% |
+673
| New | +$24.9K |
|
166
Immunovant
IMVT
$2.56B
| $23.3K | 0.01% |
1,312
+220
| +20% | +$3.91K |
|
|
SAGE
167
DELISTED
Sage Therapeutics
SAGE
| $23.1K | 0.01% |
605
+49
| +9% | +$1.87K |
|
168
BioCryst Pharmaceuticals
BCRX
$1.74B
| $21.7K | 0.01% |
1,893
+152
| +9% | +$1.75K |
|
169
Zai Lab
ZLAB
$3.68B
| $21.5K | 0.01% |
701
+51
| +8% | +$1.57K |
|
170
Revolution Medicines
RVMD
$7.1B
| $21.5K | 0.01% |
902
+81
| +10% | +$1.93K |
|
171
Krystal Biotech
KRYS
$4.27B
| $20.8K | 0.01% |
262
+22
| +9% | +$1.74K |
|
172
ImmunityBio
IBRX
$2.21B
| $20.6K | 0.01% |
4,067
+318
| +8% | +$1.61K |
|
173
Supernus Pharmaceuticals
SUPN
$2.53B
| $19.6K | 0.01% |
549
+48
| +10% | +$1.71K |
|
174
Charles River Laboratories
CRL
$8.04B
| $19.4K | 0.01% |
89
-11,677
| -99% | -$2.54M |
|
175
Ironwood Pharmaceuticals
IRWD
$214M
| $19.3K | 0.01% |
1,558
+123
| +9% | +$1.52K |
|